Document is current
Any future updates will be listed below
-
Authors
Kaufmann, Walter E.
Luu, Skylar
Budimirovic, Dejan B.
-
Funding
Funding for this research was provided by:
Simons Center for the Social Brain, at the Massachusetts Institute of Technology
International Rett Syndrome Foundation
Centers for Disease Control and Prevention Foundation
- License Information
-
More Information
Article History
Accepted: 8 October 2024
First Online: 6 December 2024
Declarations
:
: W.E.K. was the Chief Scientific Officer and currently a consultant to Anavex Life Sciences Corp., which is developing drug treatments for neurodevelopmental disorders. He has received current or past funding from Acadia, AveXis, Biohaven, EryDel/Quince, GW Pharmaceuticals, Hoffmann-La Roche, Marinus, Neuren, Newron, Novartis, Ovid, Seaside, Stalicla, Tetra, and Zynerba/Harmony for consulting and/or conducting clinical trials in neurodevelopmental disorders. D.B.B. has received current or past funding through his institution from Ovid, Seaside, and Zynerba/Harmony for consulting and/or conducting clinical trials in fragile X syndrome. S.L. reports no conflicts of interest.
: All reported studies with human subjects and animal models, performed by the authors, have been previously published and complied with all ethical standards.
